10x Genomics Reports Third Quarter 2026 Financial Results
PR Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤2026 revenue $150.7 million, up 1% year over year
- ➤Full-year 2026 revenue guidance raised to $625 million-$635 million
- ➤Gross margin expanded to 75% from 67% year over year
- ➤Operating loss narrowed to $16.1 million from $32.2 million
- ➤Global commercial shipments of Atera began amid strong early demand
Expert Statements
Serge Saxonov, Co-founder and CEO of 10x Genomics
“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers' hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables.”
Serge Saxonov, Co-founder and CEO of 10x Genomics
“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”
10x Genomics Reports Third Quarter 2026 Financial Results PR Newswire
PLEASANTON, Calif., Nov. 5, 2026 /PRNewswire/ -- 10x Genomics, Inc . (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.